fyi:
Meanwhile, ViroPharma VPHM +7.94% soared by nearly 7% to $26.07 after McMinn raised her rating to buy from neutral, and now sees a price target now of $33 a share.
McMinn sees revenue for the company's treatment for hereditary angiodema, Cinryze, at $411 million instead of $400 million for 2013, thanks to an indication from fourth-quarter sales, which were better than expected